

Supplementary Table 2. Individual patients' clinical and demographic details

Patients	Sex	Age at surgery (yr)	Disease duration (yr)	MDS-UPDRS III in "OFF" drug	Right STN width	Left STN width	Site of right STN microstimulation during RTNT (mm from anatomical target; track as defined in Bengun' device)	Site of left STN microstimulation during RTNT (mm from anatomical target; track as defined in Bengun' device)
					as defined during MER (mm; distance of superior and inferior bord from anatomical target)	as defined during MER (mm; distance of superior and inferior bord from anatomical target)		
P1	M	58	11	39	4; -2 + 1	4; -2 + 1	+1; posterior track	+1; posterior track
P2	F	53	7	40	6; -4 + 1	2; 0 + 1	N/A; posterior track	0; central track
P3	M	63	13	27	3; -2 + 0	3; -2 + 0	0; posterior track	0; anterior track
P4	F	63	10	30	5; -3 + 1	5; -2 + 2	+1; central track	+2; posterior track
P5	M	47	11	43	4; -1 + 2	6; -3 + 2	N/A; anterior track	0; posterior track
P6	M	66	11	17	5; -1 + 3	6; -3 + 2	0, +3; central track	0, +2; central track
P7	F	65	10	43	3; 0 + 2	3; -1 + 1	+2; central track	+1; central track
P8	M	57	8	30	N/A	5; -2 + 2	N/A	0,+2; central track
P9	M	57	11	48	4; -2 + 1	5; -2 + 2	0, +1; central track	0, +2; central track
P10	M	65	10	40	5; -2 + 2	6; -2 + 3	0; anterior track	0; central track
P11	F	70	13	18	4; -3 + 0	N/A	0; posterior track	0; posterior track
P12	M	50	7	29	7; -5 + 1	8; -5 + 2	0; central track	0; central track
P13	M	56	9	43	5; -3 + 1	6; -3 + 2	0; central track	0; central track
P14	M	54	6	47	3; -2 + 0	2; -1 + 0	0; central track	0; central track

MDS-UPDRS-III, Movement Disorder Society-Unified Parkinson's Disease Rating Scale III; STN, subthalamic nucleus; MER, microelectrode recording; RTNT, real-time neuropsychological testing; M, male; F, female; N/A, not applicable.